Hyponatremia and extrapontine myelinolysis in a patient with COVID-19: A case report

Muhammad Abd Ur Rehman1 | Abdulrahman Fadhl Abdulrahman2 | Aariz Zainab3 | Yahya Paksoy3 | Nadir Kharma4

1Emergency Medicine, Hamad Medical Corporation, Doha, Qatar
2Internal Medicine, Hamad Medical Corporation, Doha, Qatar
3Radiology Department, Hamad Medical Corporation, Doha, Qatar
4Critical Care Medicine, Hamad Medical Corporation, Doha, Qatar

Abstract
Until we have strong evidence to the contrary, symptomatic hyponatremia should be treated with extra caution in COVID-19 co-infection patients as the latter could be another risk factor for the development of extrapontine myelinolysis.

KEYWORDS
COVID-19, extrapontine myelinolysis, hyponatremia, ODS

1 INTRODUCTION
We present this case that led us to suspect an association between COVID-19 and extrapontine myelinolysis (EPM). It is, to the best of our knowledge, the first reported case of extrapontine myelinolysis in a patient with COVID-19 infection. We found intertwined findings of COVID-19-related encephalopathy and EPM in MRI of the patient who showed significant improvement with low-dose levodopa.

Since it was first reported in 1959,1 hundreds of case reports have been published on osmotic demyelination syndrome worldwide. It was Patricia J. et al. who raised the suspicion of association of hyponatremia with central pontine myelinolysis in 19772 and finally, four years later, rapid correction of hyponatremia was found to be the cause of central pontine myelinolysis (CPM) in rats.3

Isolated extrapontine myelinolysis (EPM), a form of osmotic demyelination, is a rare yet the most feared complication of hyponatremia correction treatment that can develop due to rapid correction of hyponatremia. A few case reports suggest successful use of high-dose levodopa for the treatment of EPM in patients who present with Parkinson’s-like symptoms.4

After the declaration of COVID-19 as a pandemic by the World Health Organization (WHO), it emerged as a serious public health challenge. We are reporting a thought-provoking case of a patient with COVID-19 infection with suspected iatrogenic development of osmotic demyelination syndrome whose brain imaging was suggestive of an intertwined picture of COVID-19-related encephalopathy along with isolated extrapontine myelinolysis. Moreover, the patient showed significant improvement after using low-dose levodopa.
## CASE DESCRIPTION

A 43-year-old man with a known history of type 2 diabetes and essential hypertension, controlled with oral hypoglycemics and combined antihypertensive drugs, respectively, presented to one of the designated COVID-19 facilities in our country with complaints of fever and cough for two days. Initial investigations revealed that he had mildly symptomatic COVID-19 pneumonia diagnosed by testing a nasopharyngeal swab sample using polymerase chain reaction (PCR) and chest X-ray. So, he was admitted for treatment and isolation.

In his initial investigations, he had significant hyponatremia (123 mmol/L) with raised serum creatinine (143 µmol/L) level while urea, potassium, and liver function tests (LFT) were within normal limits (Table 1). Management was initiated with a standard COVID-19 treatment regimen including azithromycin, amoxicillin/clavulanate, hydroxychloroquine (HCQ), and lopinavir/ritonavir in appropriate doses.

He remained asymptomatic for more than a week and serum electrolytes were never repeated till the ninth day of admission when he became disoriented and started having incomprehensible speech and an unsteady gait. At this point, a computed tomography (CT) scan of the head along with blood investigations, including serum electrolytes, was urgently obtained. The CT scan was reported as normal, but the patient’s serum sodium level was critically low (93 mmol/L) which fell to an extremely low value of 88 mmol/L in the next four hours (Table 1). Serum potassium and renal function tests (RFT) were within normal limits with deranged LFTs, most likely related to medications.

The patient was shifted to the intensive care unit (ICU) for correction of hyponatremia and neurologic observation. His initial Glasgow Coma Scale (GCS) score was 14/15, with some disorganized speech and an unsteady gait. Power, reflexes, and muscle tone were within normal limits. He received hypertonic saline (3% normal saline) for the next two days, resulting in a sodium level of 126 mmol/L (on the third day) which subsequently improved his condition clinically by day four. He was fully oriented to time, place, and person with explicit language. His GCS dropped to 10/15 on the fifth day, and he became less responsive with disorientation to time. On examination, he was moving all four limbs with osteotendinous reflexes of 3/4 in all the extremities. A repeat CT head scan revealed no ischemic changes. This was followed by a magnetic resonance imaging (MRI) of the brain which was also reported as unremarkable.

On day seven, his GCS further declined to 8/15 and he was intubated and transferred to a tertiary care facility for further management. The MRI was repeated after almost two weeks from the start of the symptoms and is shown in Figure 1. T1-weighted images (T1WI) revealed hypointense signals this time, whereas T2-weighted images (T2WI), T2-weighted fluid-attenuated inversion recovery (T2 FLAIR), and diffusion-weighted images (DWI) revealed high signal intensity in the caudate nuclei, putamen, and external capsule bilaterally, with a corresponding low signal on the apparent diffusion coefficient (ADC) map, indicating edema and restricted diffusion due to osmotic demyelination. Of particular note in this MRI study were the findings of bilateral amygdala hyperintensity on T2WI.

### Table 1: Important blood investigations

|                     | At presentation (Day 0) | At the time of Hyponatremia Symptoms (Day 9) | At the time of Resolution of Symptoms (Day 12) | At the time of Osmotic Demyelination Symptoms (Day 16) |
|---------------------|-------------------------|---------------------------------------------|-----------------------------------------------|------------------------------------------------------|
| Sodium (mmol/L)     | 123                     | 93 and 88<sup>a</sup>                       | 126                                           | 127                                                  |
| Potassium (mmol/L)  | 3.7                     | 3.5                                         | 3.9                                           | 3.6                                                  |
| Chloride (mmol/L)   | 84                      | 52.7                                        | 93.4                                          | 89.1                                                 |
| Calcium (mmol/L)    | 2.07                    | -                                           | 2.24                                          | 2.27                                                 |
| Hemoglobin (gm/dL)  | 14.6                    | 15.4                                        | 13.9                                          | 12.0                                                 |
| WBCs (×10<sup>3</sup>/µL) | 5.3                  | 16.73                                       | 14.72                                         | 12.6                                                 |
| Platelets (×10<sup>3</sup>/µL) | 130                | 257                                         | 295                                           | 267                                                  |
| Urea (mmol/L)       | 6.6                     | 5.3                                         | 6.0                                           | 8.1                                                  |
| Creatinine (µmol/L) | 143                     | 72                                          | 104                                           | 82                                                   |
| Alanine Transaminase (U/L) | 32                    | 403                                         | 271                                           | 145                                                  |
| Aspartate Transaminase (U/L) | 31                     | 169                                         | 63                                            | 40                                                   |
| Alkaline Phosphatase (U/L) | 47                    | 67                                          | 56                                            | -                                                   |

<sup>a</sup>sample repeated after 4 hours.
and FLAIR sequence shown in Figure 1B. This, with bilateral cortical gray matter swelling, goes with COVID-19-related encephalopathic changes. Over the next two days, the patient developed an increase in muscle tone, especially in the upper limbs. A low dose of carbidopa/levodopa (12.5/50 mg thrice daily) was started to ameliorate muscle rigidity. Five days later, he was successfully extubated and shifted to the medical floor.

A follow-up MRI performed nearly two months after the onset of symptoms revealed a significant interval decrease in the previously described symmetrical swelling and abnormal signal intensity in the bilateral caudate nuclei, putamen, external capsule, and cortical gray matter (Figure 2). There was a signifying improvement in edema of osmotic demyelination. The susceptibility-weighted imaging (SWI) sequence, which was unremarkable in previous Imaging, displayed susceptibility changes in the parietal, subcortical, putamen, and caudate regions in this MRI, suggestive of microhemorrhages due to COVID-19-related encephalopathy (Figure 2G).

After four months of follow-up, the patient showed considerable improvement in his cognitive and functional status. At the time of reporting this case, he was alert and oriented, but still needed assistance for physical activity.

3 | DISCUSSION

Osmotic demyelination syndrome refers to a phenomenon in which myelin from neural cells, especially oligodendrocytes, undergoes apoptosis due to the abrupt movement of intracellular water from the brain cells into the extracellular compartment. This condition has different etiologies and one of those is rapid correction of hyponatremia, which is very obvious in our case.

Serum sodium is responsible for serum tonicity. Hyponatremia results in the drop of serum tonicity that facilitate the movement of water from the extracellular compartment into brain cells, which may result in cerebral edema if it occurs acutely and dramatically. However, the brain cells can adapt by reducing the intracellular tonicity through the transport of intracellular solutes to the extracellular compartment. Through this mechanism, the brain cells remove the excess water inside the cells to prevent cerebral edema. This adaptation process usually takes 2–3 days to ensue. After these days, rapid correction of serum sodium will result in an abrupt increase in serum tonicity. Brain cells will not have the time to adapt to the new equilibrium. So, water will move extracellularly, leading to the shrinkage and apoptosis of brain cells.

FIGURE 1  Magnetic Resonance Imaging (MRI) of the brain. High signal intensity on T2 FLAIR (A) and DWI (E), while hypointense signal on T1-weighted images (H) along with corresponding low signal on ADC map (F) signify edema and restricted diffusion due to osmotic demyelination. Notice bilateral amygdala hyperintensity (black arrow in B) along with cortical gray matter swelling (C), showing COVID-19-related encephalopathic changes. No SWI changes (D, G). Symbols point out the involved regions, that is, caudate nuclei (asterisk), putamen (arrowhead), and external capsule (white arrow).

---

3 of 6
phenomenon is known as osmotic demyelination syndrome (ODS).

ODS includes two conditions, central pontine myelinolysis (CPM) and extrapontine myelinolysis (EPM). While CPM primarily affects the basis pontis, EPM mainly affects the basal ganglia, thalami, and subcortical white matter. Isolated EPM cases are rarely reported in the literature. In a large Swedish study of 83 cases of ODM, around 4% of the cases had isolated EPM. As explained before, ODS basically occurs due to the rapid correction of severe chronic hyponatremia (serum sodium less than 120 mmol/L for more than 48 h). However, there are other risk factors that increase the risk of ODS even with higher serum sodium levels. These include, but not limited to, chronic alcoholism, malnutrition, liver diseases, and hypokalemia. In chronic hyponatremia, the maximum rate of sodium correction should not exceed 8 mmol/L over 24 h. Typically, signs of ODS take 2–6 days to evolve. EPM can manifest in diverse presentations such as spastic paraparesis, mutism, catatonia, myoclonic jerks, and parkinsonian features with choreoathetosis or dystonia.

Magnetic resonance imaging (MRI) of the brain remains the gold standard modality to diagnose ODM. Nevertheless, MRI may not demonstrate the radiological features of ODM up to four weeks after the clinical manifestations have been established. In our case, early MRI brain was unremarkable. Repeating brain MRI after 1–2 weeks is recommended if there is a high clinical suspicion of ODS. For our patient, repeated brain MRI (after one week) clearly showed the features of EPM. In this case, the improvement of hyperintense signal in caudate, putamen, amygdala, and cortical gray matter with the presence of microhemorrhages on SWI on the follow-up MRI was suggestive of COVID-19-related encephalopathy findings entwined with those of extrapontine myelinolysis which might have worsened the underlying osmotic demyelination.

Regarding the treatment for ODS, supportive therapy is essential for all ODS cases. In the early stage, relowering of serum sodium showed some benefit, but the evidence is limited to animal studies and a few case reports. Plasmapheresis may improve the neurologic outcomes of ODS, according to some reports. Other treatment modalities, like corticosteroid and intravenous immunoglobulin, may be useful. However, all these options need to be further studied to clarify their role in ODS management. Some patients with predominant dystonia and muscle rigidity showed a considerable response to levodopa. Our patient received a low dose of carbidopa/levodopa. We appreciated an improvement in his clinical condition over more than four months of follow-up. Furthermore, repeated MRI brain revealed a significant improvement.

**FIGURE 2** Magnetic Resonance Imaging (MRI) of the brain. (Follow-up). Significant decrease of symmetrical swelling and abnormal signal intensity in the involved regions as compared to earlier MRI (A–F, H). SWI sequence (G) displays susceptibility changes in the parietal, subcortical, putamen, and caudate regions, suggestive of microhemorrhages due to COVID-19-related encephalopathy. Symbols are point out the involved regions, that is, caudate nuclei (asterisk), putamen (arrowhead), and external capsule (white arrow).
4 | CONCLUSION

COVID-19 is undoubtedly the most studied disease in recent years, yet there is still a lot to learn about the disease pattern. This novel case with clinical and MR findings of both COVID-19-related encephalopathy and ODS raises a question about COVID-19 as a risk factor for the development or worsening of ODS. Further studies are suggested to establish an association.

Moreover, previous data suggest some effectiveness of carbidopa/levodopa treatment at high doses only (at least 25/100 mg thrice daily) but we noticed marked improvement even with 50% of the dose reported in the literature. Investigating the optimal therapeutic dose of carbidopa/levodopa should be a key objective in future studies.

ACKNOWLEDGEMENTS
The publication of this article was funded by the Qatar National Library. We would also like to thank Dr. Hina Akram for her expert technical support in drafting the manuscript.

CONFLICT OF INTEREST
In compliance with the ICMJE uniform disclosure form, all authors declared no conflict of interest.

AUTHOR CONTRIBUTIONS
Muhammad Abd Ur Rehman: involved in data curation and wrote original draft. Abdulrahman Fadhl Al-Mashdali: validated, wrote, reviewed, and edited the manuscript. Aariz Zainab: wrote, reviewed, and edited the manuscript. Yahya Paksoy: conceptualized the study. Nadir Kharma: supervised the study.

ETHICAL APPROVAL
This article has been submitted to the Medical Research Centre in Qatar, and an approval letter was obtained from ethical committee as well as institutional review board (IRB) with approval number of MRC-04–21–226. Copies of the above-mentioned document are available to be presented to the editor-in-chief if required.

CONSENT STATEMENT
Informed verbal consent was taken from the patient while written consent was taken from the patient’s wife as the patient was unable to sign due to upper limb weakness.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

ORCID
Muhammad Abd Ur Rehman https://orcid.org/0000-0002-2566-3826

REFERENCES
1. Adams RD, Victor M, Mancall EL. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. AMA Arch Neurol Psychiatry. 1959;81(2):154-172. https://doi.org/10.1001/archneurpsyc.1959.02340140020004
2. Burcar PJ, Norenberg MD, Yarnell PR. Hyponatremia and central pontine myelinolysis. Neurology. 1977;27(3):223-226. https://doi.org/10.1212/wnl.27.3.223
3. Kleinschmidt-DeMasters BK, Norenberg MD. Rapid correction of hyponatremia causes demyelination: relation to central pontine myelinolysis. Science. 1981;211(4486):1068-1070. https://doi.org/10.1126/science.7466381
4. Abdul Halim S, Mohd Amin NA. Treatment response in osmotic demyelination disorders: central pontine and extrapontine myelinolysis. BMJ Case Rep. 2020;2020:bcr2018225751. Published 2018 Oct 21. https://doi.org/10.1136/bcr-2018-225751
5. Gankam Kengne F, Decaux G. Hyponatremia and the Brain. Kidney Int Rep. 2017;3(1):24-35. Published 2017 Sep 1. https://doi.org/10.1016/j.ekir.2017.08.015
6. Lauroeno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med. 1997;126(1):57-62. https://doi.org/10.7326/0003-4819-126-1-199701010-00008
7. Brown WD. Osmotic demyelination disorders: central pontine and extrapontine myelinolysis. Curr Opin Neurol. 2000;13(6):691-697. https://doi.org/10.1097/00019052-200012000-00014
8. Aegisdottir H, Cooray C, Wirdefeldt K, Piehl F, Sveinsson O. Incidence of osmotic demyelination syndrome in Sweden: A nationwide study. Acta Neurol Scand. 2019;140(5):342-349. https://doi.org/10.1111/ane.13150
9. George JC, Zafar W, Bucaloiu ID, Chang AR. Risk factors and outcomes of rapid correction of severe Hyponatremia. Clin J Am Soc Nephrol. 2018;13(7):984-992. https://doi.org/10.2215/CJN.13061117
10. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 Suppl 1):S1-S21. https://doi.org/10.1016/j.amjmed.2007.09.001
11. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994;4(8):1522-1530.
12. Martin RJ. Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry. 2004;75(suppl 3):iii22-iii28. https://doi.org/10.1136/jnnp.2004.045906
13. Brunner JE, Redmond JM, Haggar AM, Kruger DF, Elias SB. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. Ann Neurol. 1990;27(1):61-66. https://doi.org/10.1002/ana.410270110
14. Lampi C, Yazdi K. Central pontine myelinolysis. Eur Neurol. 2002;47(1):3-10. https://doi.org/10.1159/000047939
15. Kihira S, Delman BN, Belani P, et al. Imaging features of acute encephalopathy in patients with COVID-19: A case series. Am J Neuroradiol. 2020;41(10):1804-1808. https://doi.org/10.3174/ajnr.A6715
16. Louis G, Megarbane B, Lavoüé S, et al. Long-term outcome of patients hospitalized in intensive care units with central or extrapontine myelinolysis*. Crit Care Med. 2012;40(3):970-972. https://doi.org/10.1097/CCM.0b013e318236f152
17. Soupart A, Penninckx R, Stenuit A, Perier O, Decaux G. Reinduction of hyponatremia improves survival in rats with myelinolysis-related neurologic symptoms. *J Neuropathol Exp Neurol*. 1996;55(5):594-601. https://doi.org/10.1097/00005072-199605000-00011

18. Rondon-Berrios H. Therapeutic relowering of plasma sodium after overly rapid correction of hyponatremia: What is the evidence? *Clin J Am Soc Nephrol*. 2020;15(2):282-284. https://doi.org/10.2215/CJN.04880419

19. Bibl D, Lampl C, Gabriel C, Jüngling G, Brock H, Köstler G. Treatment of central pontine myelinolysis with therapeutic plasmapheresis. *Lancet*. 1999;353(9159):1155. https://doi.org/10.1016/S0140-6736(99)01145-9

**How to cite this article:** Abd Ur Rehman M, Abdulrahman AF, Zainab A, Paksoy Y, Kharma N. Hyponatremia and extrapontine myelinolysis in a patient with COVID-19: A case report. *Clin Case Rep*. 2021;9:e04463. https://doi.org/10.1002/ccr3.4463